NDA 020622 · Teva Pharms USA
Copaxone
Glatiramer Acetate · Subcutaneous
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jun 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Dec 20, 1996
Approved uses
3
Original approval plus efficacy supplements
Registered trials
83
27 Phase 3, 1 recruiting
FAERS reports
53,578
26,553 serious, 1,230 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLACTIC REACTIONS Cases of life-threatening and fatal anaphylaxis have been reported with COPAXONE. Anaphylaxis can occur at any time following initiation of therapy, from as early as after the first dose, up to years following initiation of therapy. Make patients aware of the symptoms of anaphylaxis, which may overlap with those of an immediate post-injection reaction; instruct them to seek immediate medical care should these symptoms occur. Prompt identification of anaphylaxis is important to avoid a delay in treatment [see Warnings and Precautions ( 5.1 )] . COPAXONE is contraindicated in patients with a history of hypersensitivity reactions to COPAXONE, including anaphylaxis. If an anaphylactic reaction occurs, treatment with COPAXONE must be immediately discontinued. Unless a clear alternative etiology is identified, COPAXONE must be permanently discontinued [see...
What it is approved for
From the label in effect Jun 23, 2026.
COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. COPAXONE is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ).
Mechanism: The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 28, 2014 Supplement 89 · Efficacy ReviewLabelLetter
- Feb 27, 2009 Supplement 57 · Efficacy LabelLetter
- Dec 20, 1996 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
- COPAXONE · GLATIRAMER ACETATE 20MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- COPAXONE · GLATIRAMER ACETATE 40MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
- COPAXONE · GLATIRAMER ACETATE 20MG/VIAL · FOR SOLUTION, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Glatiramer" as an intervention, any sponsor and status, largest first.
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00099502 · 2,244 participants · Start Nov 2003
Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) and 1 more · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 199 sites in all
- BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New DosePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00459667 · 1,420 participants · Start May 2007 · Primary completion Mar 2008
Drug: Interferon beta-1b (Betaseron, BAY86-5046); Interferon beta-1b (Betaseron, BAY86-5046) and 1 more · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 184 sites in all
- Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00451451 · 1,417 participants · Start Jun 2007 · Primary completion Aug 2011
Drug: BG00012; Placebo and 1 more · For: Relapsing-Remitting Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Huntsville, Alabama · 195 sites in all
- A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01067521 · 1,404 participants · Start Jun 22, 2010 · Primary completion May 8, 2012
Drug: Glatiramer acetate (GA); Placebo · For: Relapsing Remitting Multiple Sclerosis
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 176 sites in all
- Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).Pivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT00337779 · 1,155 participants · Start Aug 2006 · Primary completion Oct 2008
Drug: Glatiramer Acetate (GA) 40 mg; glatiramer acetate 20 mg · For: Relapsing Remitting Multiple Sclerosis
- MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxonePivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01633112 · 1,064 participants · Start Aug 9, 2012 · Primary completion Apr 30, 2018
Drug: fingolimod; glatiramer acetate · For: Relapsing-remitting Multiple Sclerosis (RRMS)
Sites: Cullman, Alabama; Phoenix, Arizona; Tucson, Arizona · 130 sites in all
- A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01216072 · 1,053 participants · Start Aug 2010 · Primary completion Aug 2012
Drug: Fingolimod; Standard MS DMTs · For: Relapsing Forms of Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 149 sites in all
- A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMSPivotal-lookingCompleted
Mapi Pharma Ltd.Industry
NCT04121221 · 1,016 participants · Start Sep 19, 2019 · Primary completion Jun 13, 2023
Drug: GA Depot · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Birmingham, Alabama; Cullman, Alabama; Pasadena, California · 112 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- multiple sclerosis relapse4,994
- drug ineffective3,700
- injection site pain3,648
- injection site reaction3,121
- fatigue3,040
- multiple sclerosis2,954
- dyspnoea2,672
- fall2,398
- gait disturbance1,983
- pain1,801
- injection site erythema1,797
- nausea1,750
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 131 |
| 2005 | 275 |
| 2006 | 353 |
| 2007 | 397 |
| 2008 | 454 |
| 2009 | 782 |
| 2010 | 1,251 |
| 2011 | 1,519 |
| 2012 | 1,790 |
| 2013 | 2,068 |
| 2014 | 4,339 |
| 2015 | 5,908 |
| 2016 | 6,614 |
| 2017 | 5,841 |
| 2018 | 5,222 |
| 2019 | 4,228 |
| 2020 | 2,729 |
| 2021 | 2,493 |
| 2022 | 2,375 |
| 2023 | 1,778 |
| 2024 | 1,347 |
| 2025 | 1,073 |
| 2026 | 610 |
Recalls
3 FDA enforcement reports for this application.
Oct 24, 2013 · Class II · Terminated
Presence of Particulate Matter: A foreign particle found in a pre-filled syringe was reported through a consumer complaint about a pre-filled syringe.
Dec 5, 2012 · Class II · Terminated
Presence of Foreign Substance: Product is being recalled due to receiving an elevated number of patient complaints related to a visible presence of medical grade silicone oil essential to the functionality of the...
May 18, 2012 · Class II · Terminated
Presence of Foreign Substance: Recall is being initiated due to the presence of a foreign particle identified from a customer complaint.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Copaxone (Glatiramer Acetate)
2024 spending
$257M
Beneficiaries
4,785
40,460 claims
Per beneficiary
$53,742
$428.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $713,588,637 |
| 2021 | $556,474,219 |
| 2022 | $456,598,003 |
| 2023 | $369,370,974 |
| 2024 | $257,157,760 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Multiple sclerosis.
Nicholas R, Chataway J · BMJ Clin Evid 2009 · Systematic Review
- Multiple sclerosis.
Nicholas R, Rashid W · BMJ Clin Evid 2012 · Systematic Review
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Multiple sclerosis.
Nicholas R, Chataway J · BMJ Clin Evid 2007 · Systematic Review
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.